NEWSROOM

OCX

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Conference Call on Wednesday, May 15, 2024, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 15, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssureTM transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024.  IVD...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Oncocyte to Announce First Quarter 2024 Financial Results

Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 13, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 12, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP $15.8 million in gross proceeds received from private placement offering $4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectively...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

-     Bio-Rad expects to make equity investment in support of deal -     Agreement provides for global exclusivity in transplant monitoring commercialization -     Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS 

Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 09, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...

read more
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

IRVINE, CA, January 16, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/ About...

read more
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Significant unmet need for regulated product in $2B US testing market Opportunity for expedited pathway for kitted product in development IRVINE, CA, December 06, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte within the recent...

read more
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is...

read more
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,...

read more
Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference.  The data was generated from a...

read more
Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 with registered investors during the conference. The Company’s virtual presentation...

read more
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX:...

read more
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte Reports Second Quarter 2023 Financial Results

Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights Transplant product launch on pace for Q4 early access. Manufacturing transfer process for 48-target universal assay began in June Expanding clinical utility for VitaGraft Kidney, a recent...

read more
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS

IRVINE, CA, August 9, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq on August 9, 2022 that it was not in compliance with the minimum bid price...

read more
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA, August 8, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for...

read more
Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Oncocyte To Announce Second Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850